View Rule

View EO 12866 Meetings

Printer-Friendly Version Download RIN Data in XML

DOJ/DEA

RIN: 1117-AB73

Publication ID: Spring 2021

Title: ●Medication-Assisted Treatment of Narcotic Withdrawal Symptoms in Hospitals
Abstract: DEA proposes to revise the existing regulations found in 21 CFR 1306.07(b), regarding expanding access to medication-assisted treatment for opioid use disorder, as instructed by Congress in Public Law 116-215 (effective December 11, 2020). The existing regulation is inadequate for emergency treatment purposes, as practitioners are prohibited from administering narcotic drugs, for the purpose of relieving acute withdrawal symptoms, to a patient for not more than one day at a time for not more than three consecutive days. DEA proposes to address the issues by allowing practitioners to provide up to a three-day supply of narcotic drugs at one time to a patient suffering from opioid withdrawal.
Agency: Department of Justice(DOJ)	Priority: Other Significant
RIN Status: First time published in the Unified Agenda	Agenda Stage of Rulemaking: Proposed Rule Stage
Major: No	Unfunded Mandates: No
CFR Citation: 21 CFR 1306
Legal Authority: 21 U.S.C. 821, 827, 871(b)

Legal Deadline:

Action	Source	Description	Date
Final	Statutory		06/09/2021

Timetable:

Action	Date	FR Cite
NPRM	10/00/2021

Regulatory Flexibility Analysis Required: No	Government Levels Affected: None
Small Entities Affected: Businesses	Federalism: No
Included in the Regulatory Plan: No
RIN Data Printed in the FR: No
Agency Contact: Scott A. Brinks Section Chief, Regulatory Drafting and Support Section, Diversion Control Division Department of Justice Drug Enforcement Administration 8701 Morrissette Drive, Springfield, VA 22152 Phone:571 362-8209 Email: scott.a.brinks@dea.gov